Cargando…

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment

Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coimbra, Judite R. M., Marques, Daniela F. F., Baptista, Salete J., Pereira, Cláudia M. F., Moreira, Paula I., Dinis, Teresa C. P., Santos, Armanda E., Salvador, Jorge A. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977085/ https://www.ncbi.nlm.nih.gov/pubmed/29881722 http://dx.doi.org/10.3389/fchem.2018.00178

Ejemplares similares

Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors
por: Coimbra, Judite R. M., et al.
Publicado: (2020)

Seizure-6 proteins highlight BACE1 functions in neurobiology
por: Pigoni, Martina, et al.
Publicado: (2016)

Structural and Functional Alterations in Mitochondria-Associated Membranes (MAMs) and in Mitochondria Activate Stress Response Mechanisms in an In Vitro Model of Alzheimer’s Disease
por: Fernandes, Tânia, et al.
Publicado: (2021)

Functions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System
por: Munro, Kathryn M., et al.
Publicado: (2016)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach
por: Baptista, Salete J., et al.
Publicado: (2017)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

Post-Translational Modifications of BACE1 in Alzheimer's Disease
por: Wen, Wen, et al.
Publicado: (2022)

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants
por: Timmers, Maarten, et al.
Publicado: (2017)

The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer’s Disease and Beyond
por: Dislich, Bastian, et al.
Publicado: (2012)

BACE1, the Alzheimer's beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2012)

BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2013)

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)

BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
por: Vassar, Robert
Publicado: (2016)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
por: Maia, Miguel A., et al.
Publicado: (2019)

BACE1: from biomarker to Alzheimer’s disease therapeutical target
por: Cervellati, Carlo, et al.
Publicado: (2021)

BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
por: Yeap, Yee Jie, et al.
Publicado: (2023)

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
por: Neumann, Ulf, et al.
Publicado: (2018)

The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer’s Disease
por: Cole, S.L, et al.
Publicado: (2007)

PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus
por: Li, Nuomin, et al.
Publicado: (2022)

Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer’s treatment
por: Jabir, Nasimudeen R., et al.
Publicado: (2021)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer’s Disease Therapy
por: Ugbaja, Samuel C., et al.
Publicado: (2022)

Platelet BACE1 levels as a possible biomarker for Alzheimer’s disease
por: Decourt, Boris, et al.
Publicado: (2013)

BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?
por: Bazzari, Firas H., et al.
Publicado: (2022)

A tale of two drug targets: the evolutionary history of BACE1 and BACE2
por: Southan, Christopher, et al.
Publicado: (2013)

Sorting out the cell biology of Alzheimer’s disease: focus on BACE1 and APP
por: Annaert, Wim
Publicado: (2012)

Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease
por: Grimmer, Timo, et al.
Publicado: (2012)

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease
por: Vassar, Robert, et al.
Publicado: (2011)

In Silico Design of BACE1 Inhibitor for Alzheimer's Disease by Traditional Chinese Medicine
por: Huang, Hung-Jin, et al.
Publicado: (2014)

Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
por: Yan, Riqiang
Publicado: (2016)

BACE1 Translation: At the Crossroads Between Alzheimer’s Disease Neurodegeneration and Memory Consolidation
por: Guix, Francesc X., et al.
Publicado: (2019)

BACE1 role in Alzheimer's disease and other dementias: from the theory to the practice
por: Cervellati, Carlo, et al.
Publicado: (2021)

Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer’s disease
por: Mukerjee, Nobendu, et al.
Publicado: (2022)

BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats
por: Weber, Martin, et al.
Publicado: (2017)

QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer’s Disease
por: Ponzoni, Ignacio, et al.
Publicado: (2019)

Calcium Modulation, Anti-Oxidant and Anti-Inflammatory Effect of Skin Allergens Targeting the Nrf2 Signaling Pathway in Alzheimer’s Disease Cellular Models
por: Silva, Ana, et al.
Publicado: (2020)

From BACE1 Inhibitor to Multifunctionality of Tryptoline and Tryptamine Triazole Derivatives for Alzheimer’s Disease
por: Jiaranaikulwanitch, Jutamas, et al.
Publicado: (2012)

Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome()
por: Mok, Kin Y., et al.
Publicado: (2014)

An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease
por: Kizuka, Yasuhiko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gnmpktk2rjs0jdebittfdtebnj